Dr Lentzsch speaks with ecancer at the 16th International Myeloma Workshop about the CASTOR trial.
The CASTOR trial is a phase III randomised controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma.
Dr Lentzsch also spoke with ecancer about the future of precision medicine in treating myeloma.
ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.